-
1
-
-
84858852559
-
sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove
-
Lopez-Sagaseta J, Puy C, Tamayo I, et al. sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove. Blood. 2012;119(12):2914-2921.
-
(2012)
Blood
, vol.119
, Issue.12
, pp. 2914-2921
-
-
Lopez-Sagaseta, J.1
Puy, C.2
Tamayo, I.3
-
2
-
-
0027943163
-
Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor
-
Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269(42):26486- 26491.
-
(1994)
J Biol Chem
, vol.269
, Issue.42
, pp. 26486-26491
-
-
Fukudome, K.1
Esmon, C.T.2
-
3
-
-
34147119744
-
The cytoprotective protein C pathway
-
DOI 10.1182/blood-2006-09-003004
-
Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161-3172. (Pubitemid 46572500)
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3161-3172
-
-
Mosnier, L.O.1
Zlokovic, B.V.2
Griffin, J.H.3
-
4
-
-
77949304898
-
APC resistance: Biological basis and acquired influences
-
Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost. 2010;8(3): 445-453.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.3
, pp. 445-453
-
-
Castoldi, E.1
Rosing, J.2
-
5
-
-
0037067752
-
The crystal structure of the endothelial protein C receptor and a bound phospholipid
-
DOI 10.1074/jbc.C200163200
-
Oganesyan V, Oganesyan N, Terzyan S, et al. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem. 2002;277(28):24851-24854. (Pubitemid 34951783)
-
(2002)
Journal of Biological Chemistry
, vol.277
, Issue.28
, pp. 24851-24854
-
-
Oganesyan, V.1
Oganesyan, N.2
Terzyan, S.3
Qu, D.4
Dauter, Z.5
Esmon, N.L.6
Esmon, C.T.7
-
6
-
-
36448952375
-
CD1 antigen presentation: How it works
-
DOI 10.1038/nri2191, PII NRI2191
-
Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7(12):929-941. (Pubitemid 350166056)
-
(2007)
Nature Reviews Immunology
, vol.7
, Issue.12
, pp. 929-941
-
-
Barral, D.C.1
Brenner, M.B.2
-
7
-
-
77649231838
-
Lipid and glycolipid antigens of CD1d-restricted natural killerTcells
-
VenkataswamyMM,Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted natural killerTcells. Semin Immunol. 2010;22(2):68-78.
-
(2010)
Semin Immunol
, vol.22
, Issue.2
, pp. 68-78
-
-
Venkataswamy, M.M.1
Porcelli, S.A.2
-
8
-
-
78650161683
-
Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: Roles as biological effectors and biomarkers
-
Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010;122(21):2183-2200.
-
(2010)
Circulation
, vol.122
, Issue.21
, pp. 2183-2200
-
-
Mallat, Z.1
Lambeau, G.2
Tedgui, A.3
-
9
-
-
33746728293
-
The endothelial protein C receptor
-
DOI 10.1097/01.moh.0000239712.93662.35, PII 0006275220060900000014
-
Esmon CT. The endothelial protein C receptor. Curr Opin Hematol. 2006;13(5):382-385. (Pubitemid 44168461)
-
(2006)
Current Opinion in Hematology
, vol.13
, Issue.5
, pp. 382-385
-
-
Esmon, C.T.1
-
10
-
-
77957692112
-
Phospholipase A2s: Developing drug targets for atherosclerosis
-
Suckling K. Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis. 2010;212(2):357-366.
-
(2010)
Atherosclerosis
, vol.212
, Issue.2
, pp. 357-366
-
-
Suckling, K.1
|